In early June 2022, a license for the use of laboratory animals had been obtained by TAIPUMED after getting approval from Science and Technology Office of Jiangsu Province, which audited its animal facility in accordance with relevant regulations such as the "Regulations on the Management of Experimental Animals" and the "Jiangsu Provincial Measures for the Management of Experimental Animals".

Since its establishment in December 2021, Taipu MedTech (Suzhou) Co., Ltd. has established a high standard preclinical and in vivo pharmacological and pharmacodynamic research service platform for large and small animals, including monkey ,minipig, dog, rabbits and rodents. The company aims to empower global pharmaceutical research and development companies with the development of large and small animal disease models, preclinical animal in vivo pharmacology and pharmacodynamics experiments, non GLP toxicological experimental research, and in vitro testing of new drugs.

Meanwhile, TAIPUMED will continue to strictly implement relevant laws and regulations, strictly adhere to standerd operating procedures, strengthen the control of laboratory animal quality and environment of facilities, and strengthen license management; we empower global customers, promote the launch of more and better new drugs, and benefit patients with unique, broad and deep animal disease models and testing systems, as well as outstanding scientific research teams.